HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Online-Only Appendix All Versions of this Article: dc07-2270v1 dc07-2270v2 31/5/845    most recent Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kahn, S. E. Search for Related Content PubMed PubMed Citation Articles by Kahn, S. E. Social Bookmarking                What's this?

Rosiglitazone Associated Fractures in Type 2 Diabetes: An Analysis From ADOPT

¹ Division of Metabolism, Endocrinology and Nutrition, Department of Internal Medicine, VA Puget Sound Health Care System and University of Washington, Seattle, WA
² Samuel Lunenfeld Research Institute, Mount Sinai Hospital and University of Toronto, Ontario, Canada
³ Biostatistics Center, George Washington University, Rockville, MD
⁴ University of Texas Health Science Center at San Antonio, San Antonio TX
⁵ Departments of Internal Medicine and Epidemiology, University of Michigan, Ann Arbor, MI
⁶ Diabetes Trials Unit, Oxford Centre for Diabetes, Endocrinology and Metabolism, Oxford, UK
⁷ GlaxoSmithKline, King of Prussia, PA
⁸ King's College London School of Medicine, King's College London, London, UK

skahn{at}u.washington.edu

ABSTRACT

Objective: To examine possible factors associated with the increased risk of fractures observed with rosiglitazone in ADOPT (A Diabetes Outcome Progression Trial).

Research Design and Methods: Data from the 1840 women and 2511 men randomized in ADOPT to rosiglitazone, metformin or glyburide for a median of 4.0 years were examined with respect to time to first fracture, rates of occurrence and sites of fractures.

Results: In men, fracture rates did not differ between treatment groups. In women, at least one fracture was reported with rosiglitazone in 60 patients (9.3% of patients, 2.74/100 patient years [PY]), metformin in 30 (5.1%, 1.54/100 PY) and glyburide in 21 (3.5%, 1.29/100 PY). The cumulative incidence (95% CI) of fractures in women at five years was 15.1% (11.2, 19.1) with rosiglitazone, 7.3% (4.4, 10.1) with metformin and 7.7% (3.7, 11.7) with glyburide, representing hazard ratios of 1.81 (1.17, 2.80) and 2.13 (1.30, 3.51) for rosiglitazone compared to metformin and glyburide, respectively. The increase in fractures with rosiglitazone occurred in pre- and postmenopausal women, and was predominantly in the lower and upper limb. No particular risk factor underlying the increased fractures in female patients who received rosiglitazone therapy was identified.

Conclusions: Further investigation into the risk factors and underlying pathophysiology for the increased fracture rate in women taking rosiglitazone is required to relate them to preclinical data and better understand the clinical implications of and possible interventions for these findings.

CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Thiazolidinediones and Fracture Risk in Diabetic Women Journal Watch Women's Health, June 26, 2008; 2008(626): 3 - 3. [Full Text]